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Introduction
Multiple sclerosis (MS) is a common immune-mediated
inflammatory disease of the central nervous system that
causes severe neurological disability [1]. Treatment is
aimed at reducing disease progression via modulation of
the immune system with disease-modifying therapies
(DMTs) such as glatiramer acetate (GA) and interferon
beta (IFN beta) [2]. Skin reactions to DMT are common
and involve localized inflammatory processes [3].
Aim
Our aim was to assess the prevalence and type of cuta-
neous adverse events associated with long-term use of
DMT.
Methods
A cross-sectional study was conducted in 2010-2011
among 15 clinics in the Netherlands. Eligible for inclu-
sion were MS patients who were treated with their first
DMT for at least 2 years. All consecutive eligible
patients willing to participate were enrolled, irrespective
of the presence of skin reactions. Skin reactions were
assessed from digital photographs of the injection-sites
by dermatologists, who were blinded for the DMT.
Results
A total of 146 patients were enrolled. The median age
was 47 years (interquartile range [IQR] 41-54 years) and
most patients (76%) were female. The median duration of
DMT treatment was 4 years (IQR 3-8). Forty-four (30%)
patients were treated with intramuscular (IM) IFN beta-
1a, 43 (29%) with subcutaneous (SC) IFN beta-1a,
38 (26%) with IFN beta-1b, and 21 (14%) with GA. The
proportion of patients with cutaneous adverse events was
40%, 77%, 63%, and 81% among patients receiving IM
IFN beta-1a, SC IFN beta-1a, SC IFN beta-1b, and GA,
respectively. Skin reactions were local injection-site reac-
tions (61%), lipoatrophy (24%), healed skin ulcers (7%),
postinflammatory hyperpigmentation (4%), urticaria (3%),
and skin necrosis (1%).
Conclusion
The prevalence of cutaneous adverse events associated
with DMT treatment was high. The most common skin
reactions were local injection-site reactions and lipoatro-
phy related to panniculitis.
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